Strattera for ADHD: how a non stimulant medication works
Let me say this right away, because it is the thing that matters most: I have not taken Strattera. I took methylphenidate, Ritalin, for four months, and I stopped. Atomoxetine I only know from the outside. Not from inside a body that has tried it.
So why this article. Because Strattera keeps showing up in people's searches: it is the best known non stimulant ADHD medication, and it is also the worst explained. You read that it "works less well", that it "does nothing", that it is "for people who cannot handle Ritalin". That is vague and sometimes wrong. I have read the literature on it, and I can at least explain clearly what we are actually talking about.
What atomoxetine actually is
Strattera is the brand name for atomoxetine. It is a non stimulant ADHD medication. In practice, that means it does not belong to the same family as Ritalin, Concerta or the amphetamines. It works on the brain differently.
Stimulants mostly raise the availability of dopamine, and also of norepinephrine, in areas tied to attention. Atomoxetine is what is called a selective norepinephrine reuptake inhibitor. It keeps norepinephrine active longer in the synaptic cleft, especially in the prefrontal cortex, the brain region that handles focus, impulse control and planning. It affects dopamine in a more indirect and more localized way. Not the broad reward circuit.
This difference is not a pharmacology footnote. It explains almost everything else: the delay before it works, the side effect profile, the fact that it is not a controlled substance and carries no real abuse potential. Atomoxetine does not produce the "kick" some people chase in stimulants. For ADHD, that is not a flaw.
The big difference from stimulants: time
Here is the point I find most important, and most misunderstood. A stimulant works the same day. The first time I took Ritalin, I felt something shift in under an hour. Atomoxetine does not work like that at all.
It is taken every day, and its effect builds gradually. Most clinical sources talk about four to six weeks, sometimes longer, before you can fairly judge whether it helps. It is not a medication you take "when you need it". It is a baseline medication, similar in its slow-onset logic to an antidepressant.
That slowness has two practical consequences. The first is that it takes patience, and patience is not exactly the ADHD brain's specialty. Many people stop too early thinking "it is not working", when they have not yet reached the window where you can judge. The second is that it covers the whole day, morning and evening included, without the late-afternoon crash I knew with immediate-release methylphenidate. You do not feel the effect rise and fall. It is smoother.
When a doctor suggests a non stimulant
Guidelines such as the UK's NICE generally place stimulants as first line in adults, because they have the strongest average effect. Atomoxetine often comes in as a second step. Here are the situations where it enters the conversation.
When stimulants have been tried and poorly tolerated. Unmanageable insomnia, too much appetite loss, rising anxiety, or the emotional flatness I went through myself. A non stimulant changes the mechanism, and sometimes that changes everything.
When there is a contraindication or specific cardiac caution, or when a doctor prefers to avoid a product with abuse potential, for example if there is a history of addiction. Atomoxetine is not a controlled substance and is not diverted.
When there is significant co-occurring anxiety. Stimulants can worsen anxiety in some people. Atomoxetine, in several studies, seems rather neutral or slightly favorable on that front. I stay careful with the word "seems", because the data is thinner than for stimulants, but it is a reason that comes up often in clinical practice.
And sometimes, simply, by preference. Someone who does not want a "switch" effect, who wants a medication they do not feel turn on every morning, can choose a non stimulant with full awareness. None of these reasons makes atomoxetine a mediocre second choice. It is a different tool.
The side effects, without playing them down
A non stimulant medication is not a medication without side effects. It would be dishonest to present it as a soft, smooth option.
The most reported effects with atomoxetine are digestive issues at the start, nausea in particular, reduced appetite, fatigue or drowsiness in some people, dry mouth, and sometimes sleep problems. It can slightly raise heart rate and blood pressure, like stimulants, which is why monitoring is needed. In adult men, sexual side effects are possible. And the label carries a warning about monitoring suicidal thoughts, especially early in treatment in younger patients, which means you are never meant to start this medication without close follow-up.
Many of these effects are stronger in the first weeks and then ease off, and they often depend on how fast the dose is increased. The "start low, go slow" principle applies here too. If something does not settle, it is to be discussed with the doctor, not endured.
The other non stimulants: guanfacine and viloxazine
Atomoxetine is not alone in the category. Two other molecules are worth naming, even if they are not all available everywhere.
Guanfacine, sold as Intuniv in its extended-release form, is an alpha-2 adrenergic receptor agonist. It started life as a blood pressure medication. It works, again, on the noradrenergic system of the prefrontal cortex, but differently from atomoxetine. It is mostly studied and approved in children and adolescents, much less in adults. It can cause drowsiness and lower blood pressure. Some doctors use it alongside a stimulant rather than on its own.
Extended-release viloxazine, marketed as Qelbree, is the most recent one. It was approved in the United States, first for children then for adults. It is also a non stimulant that acts on norepinephrine, with some action on serotonin. In much of Europe it is not currently marketed. If you hear about it, it is probably through English-language content. I mention it so you know it exists, not because it is a concrete option near you.
Finally there is bupropion, Wellbutrin, an antidepressant sometimes used off-label for ADHD. It is not an ADHD medication in the strict sense, and I cover it separately in the article on Wellbutrin and ADHD.
What I think, staying in my lane
I have not taken Strattera, so I cannot tell you "it did this to me". What I can say is what my reading taught me, and what I would have liked to know when I was asking myself questions about medication.
First, the idea that non stimulants are "weak" is a simplification. The meta-analysis by Cortese and colleagues, published in 2018, shows that stimulants have on average a stronger effect in adults. That is true on average. But an average is not a person. Someone who cannot tolerate stimulants gets no benefit from a higher average effect they cannot use. For that specific person, the right medication is the one they can take.
Second, I find the slow-onset logic interesting. Part of what bothered me with Ritalin was exactly the "switch" side: a sharp effect rising, a sharp effect falling, and the me of 7pm who was not the me of 11am. A medication that diffuses instead of hitting, on paper, speaks to me. But I do say on paper. I have not lived it.
Third, what I do not know. I do not know whether atomoxetine also gives some form of emotional flatness in certain people. I do not know how it compares to a well-dosed stimulant over the long run in real life, because studies rarely last long enough. And I do not know which non stimulant would suit any one person. Nobody knows that in advance. That is exactly the doctor's job, to feel it out with you.
If you are looking for levers outside medication, I have also written about the nootropics I have tried: it is not equivalent to a treatment and I do not claim otherwise, but it is part of the picture. And if you do not have a diagnosis yet, the real starting point is still the diagnostic process: no treatment decision is made well without it.
Frequently asked questions
Is Strattera a stimulant?
No. Strattera, or atomoxetine, is a non stimulant ADHD medication. It works mainly on norepinephrine, without the fast effect and abuse potential of stimulants like methylphenidate. It is not a controlled substance.
How long does Strattera take to work?
Atomoxetine works gradually. Most clinical sources mention four to six weeks of daily use, sometimes longer, before you can fairly judge its effectiveness. Unlike a stimulant, it does not produce an effect the same day.
Why would a doctor suggest a non stimulant ADHD medication?
Usually when stimulants have been poorly tolerated, in case of cardiac caution, when avoiding a divertible product, or with significant anxiety. The patient's preference for a smoother effect counts too. It is not a second-rank choice, it is a different mechanism.
What are the side effects of atomoxetine?
The most reported are nausea and digestive issues at the start, reduced appetite, fatigue or drowsiness, dry mouth, sometimes sleep problems and a slight rise in heart rate. The label carries a warning about monitoring mood early in treatment, which is why follow-up matters.
Is Strattera as effective as Ritalin?
On average, meta-analyses give stimulants a slightly stronger effect in adults. But an average says nothing about one specific person. For someone who cannot tolerate stimulants, a non stimulant they can actually take is the best medication, full stop.
What other non stimulant ADHD medications exist?
Alongside atomoxetine, there is extended-release guanfacine (Intuniv), mostly studied in children, and extended-release viloxazine (Qelbree), approved in the United States but not marketed across much of Europe. Bupropion (Wellbutrin) is sometimes used off-label.
References
- Cortese, S. et al. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry, 5(9), 727-738. PubMed
- National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline NG87. nice.org.uk
- Faraone, S. V. & Glatt, S. J. (2010). A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. The Journal of Clinical Psychiatry, 71(6), 754-763. PubMed